Standard BioTools Inc. (NASDAQ: LAB) is a Healthcare company (Medical - Specialties) with a market capitalization of $213M. The Maz Rating grades it against the other companies in its sector.
Standard BioTools Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $0.54, Standard BioTools Inc. trades at 2.4x sales and 0.4x book value, with an EV/EBITDA of 0.3. Over the last twelve months it generated about $87M of revenue and a net loss of $45M. It runs a gross margin of 50.8%, an operating margin of -90.6% and a net margin of -46.4%. It shows return on equity of -7.5%, return on invested capital of -6.6% and a free cash flow yield of -30.2%. On the balance sheet: a debt-to-equity ratio of 0.05 and a current ratio of 9.75. Over the past 52 weeks the share price ranged from $0.39 to $1.72, with a beta of 1.35.
Standard BioTools Inc. does not currently pay a dividend.
10 Wall Street analyst ratings cover the stock: 6 Buy and 4 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.